- Home
- ACN vs GILD Comparison
ACN vs GILD Comparison
Compare ACN & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACN | GILD |
|---|---|---|
| Founded | 1989 | 1987 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.6B | 147.6B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | ACN | GILD |
|---|---|---|
| Price | $261.64 | $124.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 22 |
| Target Price | ★ $298.82 | $123.45 |
| AVG Volume (30 Days) | 3.5M | ★ 7.1M |
| Earning Date | 12-18-2025 | 10-30-2025 |
| Dividend Yield | 2.48% | ★ 2.55% |
| EPS Growth | 6.28 | ★ 6514.05 |
| EPS | ★ 12.15 | 6.42 |
| Revenue | ★ $69,672,977,000.00 | $29,087,000,000.00 |
| Revenue This Year | $6.73 | $3.63 |
| Revenue Next Year | $5.40 | $2.97 |
| P/E Ratio | $21.61 | ★ $19.30 |
| Revenue Growth | ★ 7.36 | 2.79 |
| 52 Week Low | $229.40 | $88.57 |
| 52 Week High | $398.35 | $128.70 |
Technical Indicators
Market Signals| Indicator | ACN | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 64.30 | 51.57 |
| Support Level | $245.13 | $124.49 |
| Resistance Level | $251.94 | $128.16 |
| Average True Range (ATR) | 6.07 | 2.99 |
| MACD | 1.79 | -0.33 |
| Stochastic Oscillator | 98.06 | 33.04 |
Price Performance
Historical ComparisonAbout ACN Accenture plc (Ireland)
Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount with around 800,000 employees in over 120 countries.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).